vs
CytomX Therapeutics, Inc.（CTMX）与FrontView REIT, Inc.（FVR）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是FrontView REIT, Inc.的1.0倍（$18.7M vs $18.2M），FrontView REIT, Inc.净利率更高（2.2% vs -0.8%，领先3.0%），FrontView REIT, Inc.同比增速更快（12.0% vs -25.7%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
CTMX vs FVR — 直观对比
营收规模更大
CTMX
是对方的1.0倍
$18.2M
营收增速更快
FVR
高出37.7%
-25.7%
净利率更高
FVR
高出3.0%
-0.8%
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $18.2M |
| 净利润 | $-154.0K | $400.0K |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 24.9% |
| 净利率 | -0.8% | 2.2% |
| 营收同比 | -25.7% | 12.0% |
| 净利润同比 | 97.6% | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXFVR
| Q1 26 | — | $18.2M | ||
| Q4 25 | — | $16.5M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | $18.7M | $17.6M | ||
| Q1 25 | $50.9M | $16.2M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $14.5M | ||
| Q2 24 | $25.1M | — |
净利润CTMXFVR
| Q1 26 | — | $400.0K | ||
| Q4 25 | — | $-4.1M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $-154.0K | $-2.9M | ||
| Q1 25 | $23.5M | $-833.0K | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-2.4M | ||
| Q2 24 | $-6.5M | — |
营业利润率CTMXFVR
| Q1 26 | — | 24.9% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — |
净利率CTMXFVR
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | -24.9% | ||
| Q3 25 | — | 23.9% | ||
| Q2 25 | -0.8% | -16.5% | ||
| Q1 25 | 46.2% | -5.1% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -16.7% | ||
| Q2 24 | -26.0% | — |
每股收益（稀释后）CTMXFVR
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.19 | ||
| Q3 25 | — | $0.19 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.06 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $9.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $514.2M |
| 总资产 | $175.1M | $869.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXFVR
| Q1 26 | — | $9.3M | ||
| Q4 25 | — | $13.5M | ||
| Q3 25 | — | $19.6M | ||
| Q2 25 | $49.0M | $8.4M | ||
| Q1 25 | $47.6M | $3.3M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — |
总债务CTMXFVR
| Q1 26 | — | — | ||
| Q4 25 | — | $314.3M | ||
| Q3 25 | — | $307.1M | ||
| Q2 25 | — | $316.9M | ||
| Q1 25 | — | $310.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CTMXFVR
| Q1 26 | — | $514.2M | ||
| Q4 25 | — | $391.2M | ||
| Q3 25 | — | $385.2M | ||
| Q2 25 | $119.9M | $369.9M | ||
| Q1 25 | $25.0M | $324.7M | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $1.0K | ||
| Q2 24 | $-31.2M | — |
总资产CTMXFVR
| Q1 26 | — | $869.8M | ||
| Q4 25 | — | $854.4M | ||
| Q3 25 | — | $846.8M | ||
| Q2 25 | $175.1M | $856.5M | ||
| Q1 25 | $98.5M | $860.8M | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $1.0K | ||
| Q2 24 | $159.2M | — |
负债/权益比CTMXFVR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.80× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | — |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | — |
| 自由现金流率自由现金流/营收 | -84.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | — |
8季度趋势，按日历期对齐
经营现金流CTMXFVR
| Q1 26 | — | — | ||
| Q4 25 | — | $42.1M | ||
| Q3 25 | — | $8.3M | ||
| Q2 25 | $-15.8M | $9.3M | ||
| Q1 25 | $-21.0M | $8.1M | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.5M | — |
自由现金流CTMXFVR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — |
自由现金流率CTMXFVR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — |
资本支出强度CTMXFVR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — |
现金转化率CTMXFVR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FVR
暂无分部数据
